Xencor- Janssen Retained Rights to Develop B-Cell Targeting Cd28 Bispecific Antibodies, Including Jnj-9401 (Psma X Cd28), Jnj-1493 (Cd20 X Cd28)
xencor- Janssen保留了開發B細胞定向cd28雙特異性抗體的權利,包括Jnj-9401(Psma X Cd28)和Jnj-1493(Cd20 X Cd28)
Xencor- Janssen Retained Rights to Develop B-Cell Targeting Cd28 Bispecific Antibodies, Including Jnj-9401 (Psma X Cd28), Jnj-1493 (Cd20 X Cd28)
xencor- Janssen保留了開發B細胞定向cd28雙特異性抗體的權利,包括Jnj-9401(Psma X Cd28)和Jnj-1493(Cd20 X Cd28)
譯文內容由第三人軟體翻譯。